BAL PHARMA LTD.

Bal Pharma Ltd has responded to stock exchange queries regarding significant price movements in its scrip. The company stated that it does not possess any price-sensitive or material information that could explain the volatility. Bal Pharma confirmed that all necessary disclosures under SEBI regulations have been made within the stipulated timelines. The company attributes the price fluctuations to natural market-driven factors and denies any management involvement in influencing the share price. They reiterate their commitment to compliance and timely disclosures.

Bal Pharma Ltd has confirmed the allotment of 10,00,000 convertible warrants on a preferential basis to Mr. Shailesh Siroya, a promoter. The total issue size is ₹8.40 crore, with an issue price of ₹84 per warrant. The company has received 25% of the total amount, amounting to ₹2.10 crore. These warrants are convertible into equity shares within 18 months from the allotment date of September 7, 2026. The allotment does not change the company's paid-up equity share capital currently. Upon conversion, the new shares will rank pari passu with existing shares and will be listed on the stock exchanges.

Bal Pharma Ltd has announced September 17, 2026, as the record date for determining eligible shareholders for its final dividend. The dividend rate is fixed at ₹1.20 per equity share of ₹10 face value, representing 12% of the face value. The dividend payment is scheduled for on or after September 24, 2026. The company also provided details regarding Tax Deducted at Source (TDS) on dividend payments, advising shareholders to submit necessary forms for nil or lower TDS rates through the Registrar and Transfer Agent, MUFG Intime India Private Limited. Shareholders are urged to update their bank account details for timely credit.

Bal Pharma Limited has submitted its Annual Report for the fiscal year 2025-26, in compliance with SEBI Listing Regulations. The report, along with the notice for the 39th Annual General Meeting (AGM), is being circulated to shareholders. For members without registered email IDs, a letter with a web link to access the report online is being dispatched. The annual report is available on the company's website, www.balpharma.com, and details the company's commitment to quality healthcare and its vision for a healthier future. The filing also lists the Board of Directors, Key Management Personnel (KMPs), and various committees, along with statutory, secretarial, internal, and cost auditors, and the Registrar & Transfer Agents.

Bal Pharma Ltd has announced that its 39th Annual General Meeting (AGM) will be held on Thursday, September 24, 2026, at 11:30 AM IST. The meeting will be conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM). The notice and explanatory statement for the AGM have been circulated to members via email. The Annual Report for FY 2025-26, which includes the AGM notice, is available on the company's website. Key dates include a record date of September 17, 2026, for the final dividend, with e-voting commencing on September 21 and concluding on September 23, 2026. The book closure period is from September 18 to September 24, 2026.

Bal Pharma Limited has announced that its 39th Annual General Meeting (AGM) will be held on Thursday, September 24, 2026, at 11:30 AM IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The company has also fixed Thursday, September 17, 2026, as the Record Date for determining shareholder eligibility for the final dividend for the Financial Year 2025-26, subject to member approval. Additionally, September 17, 2026, is set as the Cut-off Date for electronic voting eligibility for the AGM resolutions. The e-voting period will commence on Monday, September 21, 2026, at 9:00 AM and conclude on Wednesday, September 23, 2026, at 5:00 PM. The Book Closure period is from Friday, September 18, 2026, to Thursday, September 24, 2026, inclusive.

Bal Pharma Ltd has issued a clarification regarding the allotment of Convertible Warrants on a preferential basis. The company confirms that the tenure of these warrants, and consequently the timeline for the utilization of net proceeds, is 18 months from the date of allotment. This clarification is in accordance with SEBI regulations and is subject to stock exchange approval. Bal Pharma emphasizes that there are no changes to the objects of the preferential issue or the manner of fund utilization.

Bal Pharma Ltd has submitted its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The results were approved by the Board of Directors during a meeting held on August 12, 2026. The company also confirmed that no funds were raised through public or preferential issues during the quarter, making the filing of a statement of deviation/variation in utilization of funds not applicable. The statutory auditors, M/s. SSJNB & Co, have issued an unmodified opinion on the financial results.

Bal Pharma Ltd's Board of Directors met on August 12, 2026, approving unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved a change in designation for two directors, effective October 1, 2026, subject to member approval. Additionally, an investment of up to ₹9 Crores in a proposed Joint Venture entity in the Philippines was approved. The company also approved the allotment of 10,00,000 warrants to a promoter for ₹8.40 Crores, with 25% of the issue price already received.

Bal Pharma Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the first quarter of the fiscal year 2026-27, ending June 30, 2026. The meeting will also address any other matters deemed necessary by the Chair, in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.